Sanofi/Regeneron's dupilumab reduces nasal polyps in PhIIa
This article was originally published in Scrip
Executive Summary
Sanofi and Regneron have released top-line Phase IIa data showing that their monoclonal antibody dupilumab met its primary and secondary endpoints in patients with chronic sinusitis with nasal polyps (CSwNP), a condition for which there are currently limited treatment options.